Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.78 HKD | +0.87% | -3.99% | -13.47% |
Mar. 22 | Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4% | MT |
Mar. 21 | Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | 246M 34.1M 267M | Sales 2024 * | 444M 61.39M 480M | Capitalization | 3.7B 512M 4.01B |
---|---|---|---|---|---|
Net income 2023 | -380M -52.59M -412M | Net income 2024 * | -251M -34.74M -272M | EV / Sales 2023 | 17 x |
Net cash position 2023 * | 962M 133M 1.04B | Net cash position 2024 * | 937M 130M 1.02B | EV / Sales 2024 * | 6.23 x |
P/E ratio 2023 |
-10.3
x | P/E ratio 2024 * |
-14.8
x | Employees | 444 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 47.57% |
1 day | +0.87% | ||
1 week | -3.99% | ||
Current month | +11.37% | ||
1 month | +11.15% | ||
3 months | -14.37% | ||
6 months | -22.21% | ||
Current year | -13.47% |
Managers | Title | Age | Since |
---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.59% | 4 M€ | -27.92% | ||
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.78 | +0.87% | 880,000 |
24-03-27 | 5.73 | 0.00% | 656,500 |
24-03-26 | 5.73 | -3.86% | 595,835 |
24-03-25 | 5.96 | -1.16% | 643,500 |
24-03-22 | 6.03 | -3.52% | 1,290,000 |
Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.47% | 508M | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |